<DOC>
	<DOCNO>NCT00016419</DOCNO>
	<brief_summary>RATIONALE : Immunosuppressive therapy may improve bone marrow abnormality may effective treatment myelodysplastic syndrome . PURPOSE : Phase II trial study effectiveness antithymocyte globulin plus cyclosporine treating patient myelodysplastic syndrome .</brief_summary>
	<brief_title>S0020 Immunosuppressive Therapy Treating Patients With Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : - Determine response patient myelodysplastic syndrome treat anti-thymocyte globulin cyclosporine . - Determine frequency severity toxic effect regimen patient . - Assess correlation response treatment vitro assessment T-lymphocyte subset patient . OUTLINE : This multicenter study . Patients stratify accord myelodysplastic syndrome subclassification ( refractory anemia [ RA ] v RA ring sideroblast vs RA excess blast ) . Patients receive induction therapy comprise anti-thymocyte globulin IV 6-12 hour day 1-4 oral cyclosporine twice daily day 5-94 followed taper day 124 . Patients relapse response least 60 day may receive reinduction therapy comprise oral cyclosporine twice daily day 1-90 followed taper day 120 . Treatment continue absence disease progression unacceptable toxicity . Patients follow monthly 6 month , every 2 month 2 year , every 6 month 3 year . PROJECTED ACCRUAL : A total 130 patient ( 53 refractory anemia [ RA ] , 33 RA ring sideroblast , 44 RA excess blast ) accrue study within 14-22 month .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Morphologically confirm myelodysplastic syndrome ( MDS ) Refractory anemia ( RA ) RA ring sideroblast RA excess blast Low , intermediate1 , intermediate2 risk International Prognostic Scoring System criterion MDS secondary prior chemotherapy and/or radiotherapy malignant disorder allow Must receive prior transfusion least 4 unit red blood cell anemia within past 60 day Must concurrently register SWOGS9910 SWOG9007 Ineligible refuse participation SWOGS9920 ( HLAidentical sibling peripheral blood stem cell transplantation ) PATIENT CHARACTERISTICS : Age : 15 Performance status : Zubrod 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No malignancy within past 2 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I II cancer complete remission HIV negative Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Prior cytokine ( e.g. , interferon interleukin ) , colonystimulating factor , epoetin alfa allow No prior bone marrow stem cell transplantation No concurrent growth factor ( include epoetin alfa ) except filgrastim ( GCSF ) sargramostim ( GMCSF ) neutropenia Chemotherapy : See Disease Characteristics No prior remission induction chemotherapy MDS Prior hydroxyurea allow Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics Surgery : Not specify Other : Prior amifostine allow No calciumchannel blocker ( diltiazem , nicardipine , verapamil ) , antifungal ( fluconazole , itraconazole , ketoconazole ) , antibiotic ( clarithromycin erythromycin ) , drug ( bromocriptine danazol ) would increase cyclosporine concentration 48 hour , , 48 hour cyclosporine No antibiotic ( nafcillin rifampin ) anticonvulsant ( carbamazepine , phenobarbital , phenytoin ) would decrease cyclosporine concentration 14 day cyclosporine</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>refractory anemia</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>